PARP Cancer Research Results

PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
2838- FIS,    Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2)
cl‑Casp3↑, cl‑PARP↑, MMP↓, Cyt‑c↑, ROS↑, NRF2↓,
2842- FIS,    Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells
- in-vitro, GC, AGS
TumCCA↑, CDK2↓, P53↑, selectivity↑, MMP↓, DNAdam↑, cl‑PARP↑, mt-ROS↑, eff↓, survivin↓,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2/PTGS2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27/CDKN1B↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2/PTGS2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
6918- FIS,  Geld,  Radic,    HSP90 Inhibitors, Geldanamycin and Radicicol, Enhance Fisetin-Induced Cytotoxicity via Induction of Apoptosis in Human Colonic Cancer Cells
- in-vitro, CRC, COLO205
eff↑, cl‑Casp3↑, PARP↑, MMPs↓, cl‑Casp9↑, other↝,
6901- FIS,    Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC
- in-vivo, HNSCC, CAL33
TumCG↓, TumCD↑, selectivity↑, TumCCA↑, CDC25↓, CDK1↓, CycB/CCNB1↓, P53↑, DNAdam↑, Apoptosis↑, γH2AX↑, cl‑PARP↑, other↝, JNK↑, PI3K↓, Akt↓, ERK↓, EGFR↓, STAT3↓, TumAuto↑, Dose↝, TumVol↓, Ki-67↓, cl‑Casp3↑, P21↓, p27/CDKN1B↓,
6899- FIS,    Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1
Dose↝, tumCV↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↑, CDK4↑, CDK6↑, P21↑, p27/CDKN1B↑, Apoptosis↑, cl‑PARP↑, Cyt‑c↑, XIAP↓, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, PI3K↓, Akt↓,
6981- Form,    Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
BioAv↝, *memory↑, *ROS↓, *AChE↓, *NF-kB↓, *Keap1↝, *NRF2↑, *Inflam↓, *PGC-1α↝, *HO-1↓, *p‑tau↓, *cognitive↑, *BDNF↑, *5HT↑, *Stroke↓, *PARP1↓, *AIF↓, *Casp3↓, NP/CIPN↓, *neuroP↑, *NGF↑, *TNF-α↓, *IL1β↓, *IL18↓, *IL6↓, *VCAM-1↓, *pol-M2 MC↑, *hepatoP↑, *AST↓, *ALAT↓, *LC3II↑, *Beclin-1↑, *p62↑, *COX2/PTGS2↑, *MMP↑, *ATP↑, *GSH↑, *Catalase↑, *GPx↑, *MDA↓, *antiPs↑, *AntiDiabetic↑, *glucose↓, *Insulin↑, *GutMicro↑, *Obesity↓, COX2/PTGS2↓, cycD1/CCND1↓, TumCCA↑, EGFR↓, GSK‐3β↑, Mcl-1↓, *toxicity↓, TumCP↓, Hif1a↓, VEGF↓, ERK↓, LAMs↓, Cyt‑c↑, Casp9↑, Casp3↑, PARP↑, TumCD↑, mitA↑, BACH1↓, P53↓, ROS↑, PD-1↓, NF-kB↓, *Bacteria↓, *AntiViral↑, *mt-ROS?, *PI3K↓, *chemoP↑, ChemoSen↑, eff↑, *toxicity↓, *BioAv↑, *BioAv↑, *eff↑,
6982- Form,    Formononetin: A Review of Its Anticancer Potentials and Mechanisms
- Review, Var, NA
AntiTum↑, Apoptosis↑, BAX↑, Bcl-2↓, Casp3↑, TumCCA↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycD1/CCND1↓, TumCP↓, VEGF↓, FGF↓, MMP2↓, MMP9↓, eff↑, ChemoSen↑, chemoPv↑, p‑Akt↓, p‑STAT3↑, TumCMig↓, TumCI↓, TIMP1↑, TIMP2↑, PI3K↓, Akt↓, Dose↝, TumCG↓, TumW↓, TumVol↓, angioG↓, Casp3↑, Casp9↑, cl‑PARP↑, DNArepair↓, MMP↓, BAX↑, Bcl-2↓, DR5↑, ROS↑, eff↓, p‑ERK↓, PTEN↑, Hif1a↓, eff↑, eff↑, ChemoSen↑, HDAC↓, *BioAv↑, *Half-Life↝, *BioAv↝, *BioAv↑, *BioAv↑, *eff↑,
6966- Form,    Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model
- NA, MM, NA
tumCV↓, Apoptosis↑, STAT3↓, STAT5↓, JAK1↓, JAK2↓, cSrc↓, ROS↑, Casp3↑, cl‑PARP↑,
6967- Form,  BTZ,    Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model
- in-vivo, Melanoma, U266 - in-vivo, Melanoma, RPMI-8226
eff↑, NF-kB↓, PI3K↓, Akt↓, AP-1↓, COX2/PTGS2↓, MMP9↓, Casp3↑, cl‑PARP↑, Dose↝, Ki-67↓, VEGF↓,
7014- Fuc,  5-FU,    Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, Colon, Caco-2
tumCV↓, ChemoSen↑, TumCCA↑, cl‑PARP↑, KRAS↓, p‑ERK↓, PI3K↓, p‑Akt↓, TumCMig↓, MMP2↓, Dose↝,
7016- Fuc,    Therapies from Fucoidan: New Developments
- Review, Var, NA
*Bacteria↓, *BioAv↓, *Dose↝, *GutMicro↑, PD-1↝, ROS⇅, cl‑Casp↑, cl‑PARP↑, RadioS↑, *radioP↑, *neuroP↑, *Aβ↓,
7006- Fuc,    Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review
- Review, Var, NA
*toxicity↓, *AntiViral↑, *antiOx↑, *Imm⇅, AntiCan↑, TumCCA↑, Apoptosis↑, TumMeta↓, angioG↓, antiNeop↑, VEGF↓, MMPs↓, BioAv↑, BioAv↑, ROS⇅, cl‑PARP↑, Casp3↑, Casp7↑, ROS↑, GSH↓, MMP↓, PI3K↓, ERK↓, MAPK↑, TumCP↓, Bax:Bcl2↑, TJ↑, ZO-1↑, OCLN↑, CLDN1↑, IBI↑, GutMicro↑, NK cell↑, STAT3↓, eff↑,
1155- Fuc,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
1086- GA,    Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation
- in-vitro, AML, K562
tumCV↓, TumCCA↑, P21↑, p27/CDKN1B↑, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Cyt‑c↑, cl‑PARP↓, DNAdam↑, Casp3↑, FASN↓, Casp8↑,
7033- GA,  OL,    Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line
- in-vitro, OS, U2OS
tumCV↓, angioG↓, DNAdam↑, Apoptosis↑, cl‑PARP↓, Bcl-2↓, BAX↑, ROS↓, eff↑, TumCMig↓, VEGF↓, Casp9↑, P53↑, selectivity↑,
7059- GamB,    Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells
- in-vitro, CRC, HCT15
TumCP↓, Apoptosis↑, JNK↑, TumCCA↑, cycD1/CCND1↓, P53↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, MMP↓, Cyt‑c↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓,
7067- GamB,    Gambogic Acid and Its Role in Chronic Diseases
- Review, Var, NA
*NF-kB↓, PI3K↓, Akt↓, STAT3↓, STAT5↓, IL6↓, COX2/PTGS2↓, iNOS↓, MMPs↓, Src↓, PKA↓, CXCR4↑, VEGF↓, Bcl-2↓, Bcl-xL↓, IAP1↓, Mcl-1↓, survivin↓, cycD1/CCND1↓, HSP90↓, HSP70/HSPA5↓, MAPK↓, HATs↓, HDAC↓, FAK↓, ROS↑, MMP7↓, MMP9↓, α-tubulin↑, cl‑PARP↑, TNF-α↓, BID↑, BAD↑, Cyt‑c↑, Casp3↑, Casp9↑, *AntiArt↑, *antiPs↑,
1961- GamB,    Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS
- in-vitro, Melanoma, RPMI-8226
TumCG↓, Apoptosis↑, ROS↑, Casp3↑, cl‑PARP↑, SIRT1↓, eff↓,
1966- GamB,  Cisplatin,    Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
- in-vitro, Lung, A549 - in-vitro, Lung, NCIH1299
TumCCA↑, PARP↑, eff↑, ROS↑, ChemoSen↑,
1967- GamB,    Gambogic acid induces apoptotic cell death in T98G glioma cells
- in-vitro, GBM, T98G
BAX↑, AIF↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↓, Bcl-2↓, ROS↑,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp/ABCB1↓, survivin↓,
7086- GAR,    Garcinol: An emerging epigenetic modifier with versatile anticancer properties
- Review, Var, NA
AntiCan↑, TumCG↓, TumMeta↓, toxicity↓, Apoptosis↑, angioG↓, *BioAv↝, HATs↓, p300↓, CBP↓, PI3K↓, Akt↓, NF-kB↓, STAT↓, mTOR↓, DFF45↓, survivin↓, N-cadherin↓, Twist↓, MMP2↓, MMP3↓, MMP9↓, Mcl-1↓, EZH2↓, NOTCH↓, CXCR4↓, PGE2↓, VEGF↓, mPGES-1↓, CycB/CCNB1↓, CDK2↓, CDK4/6↓, iNOS↓, COX2/PTGS2↓, IL1↓, TNF-α↓, PARP↑, Bcl-2↓,
810- GAR,  GEM,    Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures
- in-vitro, PC, NA
TumCP↓, Apoptosis↑, PARP↝, VEGF↝, MMPs↝, Casp↝, NF-kB↝, miR-21↝,
820- GAR,    Garcinol in gastrointestinal cancer prevention: recent advances and future prospects
- Review, NA, NA
Fas↑, TRAIL↑, PARP↑, BAX↑, Bcl-2↓, ROS↑, STAT3↓, Apoptosis↑, MMP2↓, MMP9↓,
821- GAR,    Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis
- in-vitro, Liver, Hep3B
ROS↑, CHOP/DDIT3↑, MMP↓, Bax:Bcl2↑, Casp8↑, Casp3↑, Casp9↑, cl‑PARP↑, DFF45↑,
831- GAR,  CUR,    Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells
- in-vitro, AML, HL-60
Apoptosis↑, Casp3↑, MMP↓, Cyt‑c↑, proCasp9↑, Bcl-2↓, BAX↑, PARP↓, DNAdam↑, DFF45↓,
828- GAR,  Cisplatin,    Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells
- in-vitro, Ovarian, OVCAR-3
tumCV↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, p‑PI3K↓, p‑Akt↓, NF-kB↓,
795- GAR,    Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug
- Review, NA, NA
HATs↓, BAX↑, PARP↑, Bcl-2↓, Casp3↑, Casp9↑, DR5↑, cFLIP↓, MMP2↓, MMP9↓, STAT3↓, p‑Akt↓,
7214- GAs,    Ginkgolic Acid Suppresses Nasopharyngeal Carcinoma Growth by Inducing Apoptosis and Inhibiting AKT/NF-κB Signaling
- vitro+vivo, NPC, CNE2
tumCV↓, TumCI↓, Apoptosis↑, Bcl-2↓, BAX↑, PARP↑, Casp3↑, Casp9↑, TumCCA↑, CDK6↓, CycD3↓, ChemoSen↑,
7103- GEN,    A Comprehensive Review of Genistein's Effects in Preclinical Models of Cervical Cancer
- Review, Cerv, NA
TumCP↓, Apoptosis↑, RadioS↑, ChemoSen↑, *antiOx↑, *Inflam↓, *Bacteria↓, *AntiViral↑, *AntiDiabetic↑, *neuroP↑, AntiCan↑, TumCG↓, TumCI↓, TumCCA↑, cl‑PARP↑, selectivity↑, CycB/CCNB1↓, CDK1↓, p‑cDC2↓, p‑ERK↓, p‑p38↑, p‑JNK↑, MMP9↓, TIMP1↑, BioAv↓, BioAv↑, Half-Life↑,
7217- GGB,    Role of Ginkgolides in the Inflammatory Immune Response of Neurological Diseases: A Review of Current Literatures
- Review, AD, NA
*eff↑, *AntiAg↑, *Apoptosis↓, *antiOx↑, *Inflam↓, *MAPK↓, *NF-kB↓, *PAF↓, *TLR1↓, *MyD88↓, *BDNF↑, *ROS↓, *PARP↓, *Cyt‑c↓,
7138- GI,    6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Pca, DU145 - in-vitro, Liver, HepG2 - in-vitro, Lung, A549
TumCP↓, TumMeta↓, p‑STAT3↓, JAK2↓, cSrc↓, JNK↑, p38↑, ERK↑, eff↓, ROS↑, cl‑PARP↑, TumCCA↑, Casp8↑, Casp9↑, Casp3↑, eff↑, Bcl-2↑, Bcl-xL↓, survivin↓, MMP9↓, COX2/PTGS2↓, IAP1↓, Dose?,
7247- Gink,    Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT474 - vitro+vivo, BC, MCF7
TumCP↓, Apoptosis↑, TumCG↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, Bcl-2↓, survivin↓, p‑ERK↑, cl‑JNK↑,
7250- Gink,    Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy
- Review, Var, NA
AntiCan↑, toxicity↓, ChemoSen↑, chemoP↑, TumCCA↑, TumCD↑, TumCI↓, angioG↓, Ferroptosis↑, Imm↑, MOMP↑, Cyt‑c↑, Casp↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Apoptosis↑, ROS↑, TumAuto↑, GPx4↓, xCT/SLC7A11↓, RadioS↑, NRF2↓, HO-1↓, HSP90↓, Dose↝, Dose↝, BioAv↓, BioAv↝, CYP3A4↓, *toxicity↑, *toxicity↝,
7260- Gink,    Ginkgetin: A natural biflavone with versatile pharmacological activities
- Review, Var, NA - Review, Stroke, NA - Review, AD, NA
*AntiCan↑, *Inflam↓, *AntiBio↑, *neuroP↑, *TumCCA↑, Apoptosis↑, TumAuto↑, iNOS↓, COX2/PTGS2↓, PGE2↓, NF-kB↓, PLA2↓, *neuroP↑, *Stroke↓, *AntiFungal↓, *Bacteria↓, Bcl-xL↓, Bcl-2↓, Casp9↑, Casp3↑, cl‑PARP↑, IL6↓, STAT3↓, JAK1↓, survivin↓, COX2/PTGS2↓, IAP1↓, MMP2↓, MMP9↓, PTEN↑, SHP1↑, eff↑, TumVol↓, TumW↓, *toxicity↓, *ROS↓,
7259- Gink,    Ginkgetin induces apoptosis via activation of caspase and inhibition of survival genes in PC-3 prostate cancer cells
- in-vitro, Pca, PC3
tumCV↓, TumCCA↑, Casp3↑, Bcl-2↓, Bcl-xL↓, survivin↓, cycD1/CCND1↓, cl‑PARP↑,
7315- Gos,    Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells
- vitro+vivo, CRC, HT29 - in-vitro, CRC, COLO205
TumCD↑, Casp3↑, Casp6↑, Casp8↑, Casp9↑, cl‑PARP↑, Bcl-xL↓, ROS↑, i-H2O2↑, eff↓, mtDam↑, MMP↓, Cyt‑c↑, AIF↑, TumCG↓,
843- Gra,    Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling
- in-vitro, NMSC, A431 - in-vitro, NMSC, UW-BCC1 - in-vitro, Nor, NHEKn
TumCG↓, TumCCA↑, Cyc↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, Sufu↑, BAX↑, Bcl-2↓, *toxicity↓,
1657- HCAs,    Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line 2023
- in-vitro, CRC, HT-29
cl‑Casp3↑, BAX↑, cl‑PARP↑, γH2AX↑, Cyt‑c↑,
1912- HCQ,  TMZ,    Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy
- in-vivo, GBM, U87MG
LC3B-II↑, CHOP/DDIT3↑, cl‑PARP↑,
7466- HNK,  PDT,  MET,    Enhanced integrated therapy for breast cancer employing Honokiol-loaded mesoporous polydopamine nanoparticles in conjunction with photothermal effects and low-dose metformin
- in-vitro, BC, NA
TumCD↓, Dose↝, cl‑Casp3↑, cl‑PARP↑, Apoptosis↑, TumCP↓,
7463- HNK,    Honokiol Inhibits Colorectal Cancer Cell Growth: Involvement of Hsp27 as a Molecular Target
- in-vitro, CRC, NA
TumCG↓, TumCCA↑, Cyt‑c↑, Apoptosis↑, cl‑PARP↑, Bcl-2↓, HSP27↓,
2867- HNK,    Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway
- in-vitro, Nor, C2C12
*antiOx↑, *ROS↓, *Bcl-2↑, *BAX↓, Casp9∅, Casp3∅, cl‑PARP∅, Cyt‑c?,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2/KDR/Flk1↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2/PTGS2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP/DDIT3↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp/ABCB1↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2/PTGS2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
1286- HNK,    The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
- in-vitro, CLL, NA
Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Bcl-2↓, BAX↑,
1154- HNK,  MET,    Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin
- in-vitro, BC, MCF7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
cl‑PARP↑, Bcl-2↓, ERα/ESR1↓,
2073- HNK,    Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo
- in-vitro, OS, U2OS - in-vivo, NA, NA
TumCD↑, TumAuto↑, Apoptosis↑, TumCCA↑, GRP78/BiP↑, ROS↑, eff↓, p‑ERK↑, selectivity↑, Ca+2↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, survivin↓, LC3B-II↑, ATG5↑, TumVol↓, TumW↓, ER Stress↑,

Showing Research Papers: 201 to 250 of 391
Prev Page 5 of 8 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 391

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PLA2↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   i-H2O2↑, 1,   HO-1↓, 1,   Keap1↓, 1,   NRF2↓, 2,   NRF2↑, 2,   ROS↓, 2,   ROS↑, 19,   ROS⇅, 2,   mt-ROS↑, 1,   SIRT3↑, 1,   TrxR1↓, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 3,   CDC25↓, 1,   MMP↓, 12,   mtDam↑, 2,   c-Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 3,   ATG7↑, 1,   cMyc↓, 1,   CYP3A4↓, 1,   FASN↓, 1,   SIRT1↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 11,   p‑Akt↓, 4,   APAF1↑, 1,   Apoptosis↑, 23,   BAD↑, 1,   Bak↑, 2,   BAX↑, 14,   Bax:Bcl2↑, 4,   Bcl-2↓, 22,   Bcl-2↑, 1,   Bcl-xL↓, 8,   BID↑, 3,   BIM↑, 1,   Casp↑, 3,   Casp↝, 1,   cl‑Casp↑, 1,   Casp3↑, 27,   Casp3∅, 1,   cl‑Casp3↑, 10,   Casp6↑, 1,   Casp7↑, 2,   Casp8↑, 9,   cl‑Casp8↑, 3,   Casp9↑, 20,   Casp9∅, 1,   cl‑Casp9↑, 4,   proCasp9↑, 1,   CBP↓, 1,   cFLIP↓, 1,   Cyt‑c↑, 16,   Cyt‑c?, 1,   Diablo↑, 1,   DR5↑, 3,   FADD↑, 1,   Fas↓, 1,   Fas↑, 2,   FasL↑, 1,   Ferroptosis↑, 1,   IAP1↓, 3,   iNOS↓, 4,   JNK↑, 4,   p‑JNK↑, 1,   cl‑JNK↑, 1,   MAPK↓, 4,   MAPK↑, 1,   Mcl-1↓, 7,   Mcl-1↑, 1,   MDM2↓, 1,   MOMP↑, 1,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 3,   p38↑, 1,   p‑p38↑, 1,   survivin↓, 12,   TRAIL↑, 1,   TumCD↓, 1,   TumCD↑, 5,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 3,   EF-1α↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   cJun↑, 1,   EZH2↓, 1,   H3↑, 1,   H4↑, 1,   HATs↓, 3,   HATs↑, 1,   miR-21↝, 1,   other↝, 2,   tumCV↓, 9,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   cl‑CHOP/DDIT3↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 3,   HSF1↓, 1,   HSP27↓, 1,   HSP27↝, 1,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↝, 1,   HSP90↓, 3,   IRE1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 2,   LC3B-II↑, 2,   LC3II↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 2,   DFF45↑, 1,   DNAdam↑, 8,   DNArepair↓, 1,   P53?, 1,   P53↓, 1,   P53↑, 7,   PARP↓, 1,   PARP↑, 8,   PARP↝, 1,   cl‑PARP↓, 3,   cl‑PARP↑, 35,   cl‑PARP∅, 1,   PCNA↓, 1,   γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 5,   CDK2↑, 1,   CDK4↓, 3,   CDK4↑, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 10,   CycD3↓, 1,   cycE/CCNE↓, 4,   mitA↑, 1,   P21?, 1,   P21↓, 1,   P21↑, 4,   p‑RB1↓, 1,   TumCCA↑, 23,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   p‑cDC2↓, 1,   cFos↓, 2,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 6,   ERK↑, 1,   p‑ERK↓, 3,   p‑ERK↑, 2,   FGF↓, 1,   Gli1↓, 1,   GSK‐3β↑, 1,   HDAC↓, 3,   HH↓, 1,   IGF-1↓, 1,   mTOR↓, 5,   mTORC1↓, 1,   Nanog↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   NOTCH3↓, 1,   OCT4↓, 1,   p300↓, 1,   PI3K↓, 11,   p‑PI3K↓, 1,   PTEN↑, 3,   RAS↓, 1,   Shh↓, 1,   SHP1↑, 1,   Smo↓, 1,   SOX2↓, 1,   Src↓, 1,   STAT↓, 1,   STAT3↓, 10,   p‑STAT3↓, 1,   p‑STAT3↑, 1,   STAT5↓, 2,   Sufu↑, 1,   TCF-4↓, 1,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 9,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

AP-1↓, 2,   BACH1↓, 1,   Ca+2↑, 1,   CDK4/6↓, 1,   CLDN1↑, 1,   E-cadherin↑, 1,   EM↑, 1,   FAK↓, 1,   GLI2↓, 1,   Ki-67↓, 2,   KRAS↓, 1,   LAMs↓, 1,   MMP1↓, 1,   MMP2↓, 8,   MMP3↓, 2,   MMP7↓, 3,   MMP9↓, 11,   MMPs↓, 4,   MMPs↝, 1,   N-cadherin↓, 1,   PKA↓, 1,   Slug↓, 1,   Snail↓, 1,   SOX4↓, 1,   TIMP1↑, 2,   TIMP2↑, 1,   TJ↑, 1,   TumCI↓, 7,   TumCMig↓, 4,   TumCP↓, 10,   TumMeta↓, 7,   Twist↓, 3,   uPA↓, 1,   Vim↓, 1,   Zeb1↓, 1,   ZO-1↑, 1,   α-tubulin↑, 1,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   ATF4↑, 1,   EGFR↓, 5,   Hif1a↓, 3,   NO↓, 1,   VEGF↓, 9,   VEGF↝, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,   OCLN↑, 1,   P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 11,   CXCR4↓, 1,   CXCR4↑, 1,   IKKα↓, 1,   IL1↓, 1,   IL1β↓, 1,   IL6↓, 4,   Imm↑, 1,   Inflam↓, 1,   JAK1↓, 3,   JAK2↓, 3,   mPGES-1↓, 1,   NF-kB↓, 11,   NF-kB↝, 1,   NK cell↑, 1,   p65↓, 1,   PD-1↓, 1,   PD-1↝, 1,   PGE2↓, 6,   TNF-α↓, 4,  

Cellular Microenvironment(tgid=17) ⓘ

IM↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 4,   CDK6↑, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 3,   ChemoSen↑, 12,   Dose?, 1,   Dose↝, 9,   eff↓, 6,   eff↑, 13,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 3,   RadioS↑, 5,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 5,   ERα/ESR1↓, 1,   EZH2↓, 1,   GutMicro↑, 1,   IL6↓, 4,   Ki-67↓, 2,   KRAS↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 5,   antiNeop↑, 1,   AntiTum↑, 1,   chemoP↑, 2,   chemoPv↑, 1,   NP/CIPN↓, 1,   OS↑, 1,   toxicity↓, 3,   TumVol↓, 4,   TumW↓, 3,  
Total Targets: 293

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   AntiBio↑, 1,   PAF↓, 1,   Stroke↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 5,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   HO-1↓, 1,   Keap1↝, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 5,   mt-ROS?, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↓, 1,   ATP↑, 1,   Insulin↑, 1,   MMP↑, 1,   PGC-1α↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   glucose↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c↓, 1,   MAPK↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↓, 1,   PARP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   VCAM-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↑, 1,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm⇅, 1,   Inflam↓, 5,   pol-M2 MC↑, 1,   MyD88↓, 1,   NF-kB↓, 3,   TLR1↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 1,   BDNF↑, 2,   NGF↑, 1,   p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 5,   BioAv↝, 2,   Dose↝, 1,   eff↑, 3,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 2,   antiPs↑, 2,   chemoP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 6,   Obesity↓, 1,   radioP↑, 1,   toxicity↓, 6,   toxicity↑, 1,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↓, 1,   AntiViral↑, 3,   Bacteria↓, 4,  
Total Targets: 80

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
16 Apigenin (mainly Parsley)
16 Curcumin
15 Fisetin
14 Thymoquinone
13 Quercetin
12 Baicalein
10 EGCG (Epigallocatechin Gallate)
10 Sulforaphane (mainly Broccoli)
8 Honokiol
8 Shikonin
7 Ashwagandha(Withaferin A)
7 Berberine
7 Capsaicin
7 Emodin
7 Garcinol
6 Metformin
6 Boswellia (frankincense)
6 Carnosic acid
6 Chrysin
6 Gambogic Acid
6 isoorientin
6 Piperlongumine
6 Vitamin C (Ascorbic Acid)
5 Betulinic acid
5 Eugenol
5 Silymarin (Milk Thistle) silibinin
4 doxorubicin
4 Bufalin/Huachansu
4 α-Bisabolol / Chamomile oil
4 Carvacrol
4 chaetocin
4 Citric Acid
4 Docetaxel
4 Evodiamine
4 Formononetin
4 Fucoidan
4 Ginkgetin
4 Nimbolide
4 Propolis -bee glue
4 Phenethyl isothiocyanate
4 Resveratrol
3 Auranofin
3 Allicin (mainly Garlic)
3 5-fluorouracil
3 Cisplatin
3 Brucea javanica
3 Thymol-Thymus vulgaris
3 Ellagic acid
3 Ferulic acid
3 HydroxyTyrosol
3 Isobavachalcone
3 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
3 Isoliquiritigenin
3 Magnetic Fields
3 Propyl gallate
3 α-Santalol/Sandalwood oil
2 1,8-Cineole
2 Silver-NanoParticles
2 Artemisinin
2 Berbamine
2 Beta-Caryophyllene
2 temozolomide
2 brusatol
2 Boron
2 Radiotherapy/Radiation
2 Cichoric acid / Chicoric acid
2 Cinnamon
2 Cucurbitacin
2 Cynaropicrin
2 Dichloroacetate
2 D-limonene
2 Dandelion Root
2 Echinacea
2 Ginkgo biloba-EGb 761
2 Eurycomanone
2 Gallic acid
2 Photodynamic Therapy
2 Hyperoside
2 Indole-3-carbinol
2 isoquercitrin
2 Juglone
2 Luteolin
2 Lycopene
2 Magnolol
2 Phenylbutyrate
2 Paclitaxel/Taxol
2 Piperine
2 Rosmarinic acid
2 salinomycin
2 Selenite (Sodium)
2 Ursolic acid
2 Urolithin
1 3-bromopyruvate
1 DTS(dibenzyl trisulphide) from Anamu
1 Anethole/trans-Anethole
1 Fennel Oil/Foeniculum vulgare
1 immunotherapy
1 Atorvastatin
1 Aloe anthraquinones
1 Baicalin
1 almonertinib
1 Bromelain
1 Butyrate
1 Sorafenib (brand name Nexavar)
1 Cat’s Claw
1 Celastrol
1 Chlorogenic acid
1 Chlorophyllin
1 Coenzyme Q10
1 Carvone
1 Dichloroacetophenone(2,2-)
1 Date Fruit Extract
1 Fenbendazole
1 Geldanamycin
1 Radicicol/monorden
1 Bortezomib
1 olaparib/LYNPARZA
1 Gemcitabine (Gemzar)
1 Ginkgolic acids
1 Genistein (soy isoflavone)
1 Ginkgolide B
1 Ginger/6-Shogaol/Gingerol
1 Gossypol/AT-101
1 Graviola
1 Hydroxycinnamic-acid
1 hydroxychloroquine
1 Rutin
1 isoflavones
1 Isovitexin
1 lambertianic acid
1 Methylene blue
1 Chemotherapy
1 Myricetin
1 nelfinavir/Viracept
1 Oleuropein
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Plumbagin
1 VitK3,menadione
1 Rauwolfia serpentina/Indian Snakeroot
1 Selenium NanoParticles
1 chitosan
1 Folic Acid, Vit B9
1 Osimertinib
1 Adagrasib
1 Terpinen-4-ol / Tea Tree Oil
1 Aflavin-3,3′-digallate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:239  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page